These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 15088311)

  • 1. Serum level of KL-6 as a marker of interstitial lung disease in patients with juvenile systemic sclerosis.
    Veselý R; Vargová V; Ravelli A; Massa M; Oleksák E; D'Alterio R; Martini A; De Benedetti F
    J Rheumatol; 2004 Apr; 31(4):795-800. PubMed ID: 15088311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KL-6 is a potential marker for interstitial lung disease associated with juvenile dermatomyositis.
    Kobayashi I; Ono S; Kawamura N; Okano M; Miyazawa K; Shibuya H; Kobayashi K
    J Pediatr; 2001 Feb; 138(2):274-6. PubMed ID: 11174630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
    Yamane K; Ihn H; Kubo M; Yazawa N; Kikuchi K; Soma Y; Tamaki K
    J Rheumatol; 2000 Apr; 27(4):930-4. PubMed ID: 10782818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis.
    Yanaba K; Hasegawa M; Takehara K; Sato S
    J Rheumatol; 2004 Jun; 31(6):1112-20. PubMed ID: 15170923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
    Asano Y; Ihn H; Yamane K; Yazawa N; Kubo M; Fujimoto M; Tamaki K
    Arthritis Rheum; 2001 Jun; 44(6):1363-9. PubMed ID: 11407696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical significance of serum KL-6 and SP-D for the diagnosis and treatment of interstitial lung disease in patients with diffuse connective tissue disorders].
    Ogawa N; Shimoyama K; Kawabata H; Masaki Y; Wano Y; Sugai S
    Ryumachi; 2003 Feb; 43(1):19-28. PubMed ID: 12692986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases.
    Nakajima H; Harigai M; Hara M; Hakoda M; Tokuda H; Sakai F; Kamatani N; Kashiwazaki S
    J Rheumatol; 2000 May; 27(5):1164-70. PubMed ID: 10813282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
    Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Assessment of serum markers KL-6 and SP-D for interstitial pneumonia associated with connective tissue diseases].
    Suematsu E; Miyamura T; Shimada H; Nakao R; Yamamoto M
    Ryumachi; 2003 Feb; 43(1):11-8. PubMed ID: 12692985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum KL-6 and surfactant proteins A and D in pediatric interstitial lung disease.
    Al-Salmi QA; Walter JN; Colasurdo GN; Sockrider MM; Smith EO; Takahashi H; Fan LL
    Chest; 2005 Jan; 127(1):403-7. PubMed ID: 15654008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Use of the the ED046 kit to analyze serum KL-6 in patients with pneumonitis].
    Kitamura S; Hiwada K; Kobayashi J; Kohno N; Kawai T; Satou A; Kasukawa R; Kawakami Y; Andou M; Nakada G; Inoue H; Itou K; Matsushima T; Ogura T; Arakawa M; Yamakido M
    Nihon Kyobu Shikkan Gakkai Zasshi; 1996 Jun; 34(6):639-45. PubMed ID: 8741528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases.
    Satoh H; Kurishima K; Ishikawa H; Ohtsuka M
    J Intern Med; 2006 Nov; 260(5):429-34. PubMed ID: 17040248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum marker KL-6/MUC1 for the diagnosis and management of interstitial pneumonitis.
    Kohno N
    J Med Invest; 1999 Aug; 46(3-4):151-8. PubMed ID: 10687309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical usefulness of KL-6 as a serum marker of idiopathic interstitial pneumonia].
    Kohno N
    Nihon Kyobu Shikkan Gakkai Zasshi; 1996 Dec; 34 Suppl():186-9. PubMed ID: 9216213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The clinical study on KL-6 and SP-D in sera of patients with various pulmonary diseases].
    Sugimoto H; Okada E; Hashimoto N; Suzuki S; Yoshida H; Totani Y; Ameshima S; Ishizaki T; Miyamori I
    Rinsho Byori; 2000 Jun; 48(6):554-60. PubMed ID: 10897675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.
    Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y
    Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis.
    Kodera M; Hasegawa M; Komura K; Yanaba K; Takehara K; Sato S
    Arthritis Rheum; 2005 Sep; 52(9):2889-96. PubMed ID: 16142750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.
    Khanna D; Clements PJ; Furst DE; Chon Y; Elashoff R; Roth MD; Sterz MG; Chung J; FitzGerald JD; Seibold JR; Varga J; Theodore A; Wigley FM; Silver RM; Steen VD; Mayes MD; Connolly MK; Fessler BJ; Rothfield NF; Mubarak K; Molitor J; Tashkin DP;
    Arthritis Rheum; 2005 Feb; 52(2):592-600. PubMed ID: 15692967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers to identify ILD and predict lung function decline in scleroderma lung disease or idiopathic pulmonary fibrosis.
    Kennedy B; Branagan P; Moloney F; Haroon M; O'Connell OJ; O'Connor TM; O'Regan K; Harney S; Henry MT
    Sarcoidosis Vasc Diffuse Lung Dis; 2015 Sep; 32(3):228-36. PubMed ID: 26422568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease.
    Launay D; Mouthon L; Hachulla E; Pagnoux C; de Groote P; Remy-Jardin M; Matran R; Lambert M; Queyrel V; Morell-Dubois S; Guillevin L; Hatron PY
    J Rheumatol; 2007 May; 34(5):1005-11. PubMed ID: 17444586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.